Novo Nordisk As Stock Total Asset
| 0QIU Stock | 742.30 14.79 2.03% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Stock. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 223.7 B | 149.2 B |
Novo | Total Asset |
Novo Nordisk AS Company Total Asset Analysis
Novo Nordisk's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Novo Nordisk Total Asset | 194.51 B |
Most of Novo Nordisk's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Novo Total Assets
Total Assets |
|
Based on the latest financial disclosure, Novo Nordisk AS has a Total Asset of 194.51 B. This is much higher than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The total asset for all United Kingdom stocks is significantly lower than that of the firm.
Novo Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in total asset category among its peers.
Novo Nordisk ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novo Nordisk's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novo Nordisk's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Novo Fundamentals
| Return On Equity | 0.82 | ||||
| Return On Asset | 0.22 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 2.96 T | ||||
| Shares Outstanding | 2.41 B | ||||
| Shares Owned By Insiders | 5.98 % | ||||
| Shares Owned By Institutions | 41.95 % | ||||
| Price To Sales | 0.12 X | ||||
| Revenue | 140.8 B | ||||
| Gross Profit | 148.51 B | ||||
| EBITDA | 92.89 B | ||||
| Net Income | 47.76 B | ||||
| Total Debt | 12.96 B | ||||
| Book Value Per Share | 40.37 X | ||||
| Cash Flow From Operations | 55 B | ||||
| Earnings Per Share | 21.50 X | ||||
| Number Of Employees | 59.34 K | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 19.9 B | ||||
| Total Asset | 194.51 B | ||||
| Retained Earnings | 72 B | ||||
| Net Asset | 194.51 B | ||||
| Last Dividend Paid | 14.15 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novo Stock Analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.